The relationship between radiotherapy efficacy and statin (St) use in prostate cancer (PC): A retrospective study.

Abstract

e15100 Background: Preclinical antiproliferative, proapoptotic, and radiosensitizing St properties have been previously described. In addition, St use has been associated with a lower risk of PC incidence, low prostate-specific antigen (PSA) at diagnosis and longer freedom from biochemical recurrence (FFBR). The aim of this study was to correlate pre-radiotherapy St use with the risk of biochemical relapse in PC patients (pts) treated with radical radiotherapy (RT) with concurrent androgen deprivation. Methods: Medical reports of 204 pts diagnosed with PC between 2000 and 2005 were reviewed, with a median follow-up of 54 months. Univariate and multivariate analysis were performed. Variables included were PSA at diagnosis, St treatment, clinical T stage (T1-2a vs T2b-c vs T3-4) and Gleason Score (GS). According to NCCN guidelines, risk category was defined as low (T1-T2a and PSA≤10 and GS ≤ 6), intermediate (T2b or 10<PSA<20 or GS=7) or high risk (≥T2c or PSA≤20 or GS 8-10). ASTRO criteria were used for biochemical progression. Results: Median (M) age was 71 y (range 47-84) and M radiation dose was 74 Gy. Twelve (6%), 41 pts (20%) and 149 pts (74%) were classified as low, medium and high risk respectively. Forty-six pts (23%) were taking St at diagnosis. No statistical differences were found between treatment groups regarding M age, risk category, clinical T stage, GS or M radiation dose. However, pts treated with St had a lower M PSA at diagnosis (7.95 vs 12.95) (p=0,197). At the time of analysis, only 32 pts (15.7%) had biochemical relapse (4 low risk, 6 intermediate, and 21 high risk). St use was not significantly associated with improved FFBR (p=0.641), regardless of risk group. In the multivariate analysis, none of the previous items was associated with FFBR. Conclusions: In our cohort, St use was not associated with a significant improvement in FFBR, in either risk group. Although there could be a bias due to the proportion of pts with high risk features with low rate of biochemical relapses. Our findings warrant further investigation.